1. Short title This Act may be cited as the Prescription Drug Price Reporting Act . 2. Prescription drug price reporting requirements (a) Submission of data (1) In general Each manufacturer of a prescription drug shall submit to the Secretary, electronically, in such manner as the Secretary may require, by April 1 of each year, a list of each such drug that is marketed in the United States and, with respect to each such drug, all of the following information with respect to the previous year: (A) Each applicable National Drug Code (or J-Code). (B) Brand name. (C) Generic name and chemical name, as applicable. (D) Therapeutic class or classes, as applicable. (E) Current wholesale acquisition cost per 30-day supply or typical course of treatment. (F) Average wholesale acquisition cost for the drug per 30-day supply or typical course of treatment during the previous calendar year, or, in the case of a drug that has been marketed for only a portion of such year, during the portion of time in such year that the drug was marketed. (G) Average net price per 30-day supply or typical course of treatment, during the previous calendar year, or, in the case of a drug that has been marketed for only a portion of such year, during the portion of time in such year that the drug was marketed, taking into account all discounts, rebates, and other fees or payments to health insurance plans or pharmacy benefit managers with respect to sales of the drug to individuals covered by such a plan. (H) Total rebates and other payments to health insurance plans or pharmacy benefit managers, per 30-day supply or typical course of treatment, with respect to individuals covered by such a plan, during the previous calendar year, or, in the case of a drug that has been marketed for only a portion of such calendar year, during the portion of time in such calendar year that the drug was marketed. (2) Timeline for initial submission (A) Drugs marketed before December 31, 2020 Each manufacturer of a prescription drug that is marketed at any time